Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine.

摘要: Telcagepant is an oral calcitonin-gene related peptide (CGRP) receptor antagonist that being developed by Merck & Co Inc for the treatment of migraine. This compound blocks CGRP receptors and may block dilation dural vessels reduce neurotransmission in CNS, resulting pain relief. does not cause vasoconstriction, one major limitations use triptans, which are considered to be standard care Data from phase II III clinical trials suggest telcagepant acute migraine was comparable with triptan compounds superior placebo all primary endpoints, including relief freedom at 2 h. However, recent data reported elevated transaminase levels when dosed daily rather than acutely. It concluded that, if these hepatic toxicities observed ongoing/future telcagepant, then this agent offer alternative therapy